GMAB

Genmab AS (GMAB)

Genmab AS

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:GMAB

1 2 3 4 5 6 7 8 9 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/09/15	21:45	Business Wire	Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial	NASDAQ:GMAB	Genmab AS
2024/09/12	04:47	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/09/11	05:16	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/08/21	23:50	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/08/20	03:00	Business Wire	TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	NASDAQ:GMAB	Genmab AS
2024/08/16	22:00	Business Wire	Genmab Announces Changes to its Executive Committee	NASDAQ:GMAB	Genmab AS
2024/08/14	23:48	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/08/14	03:57	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/08/05	19:28	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/07/17	23:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/06/28	15:00	Business Wire	Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma	NASDAQ:GMAB	Genmab AS
2024/06/27	08:08	Business Wire	EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)	NASDAQ:GMAB	Genmab AS
2024/06/13	04:50	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/06/12	04:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/06/11	01:51	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/06/04	05:23	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/06/03	22:00	Business Wire	Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)	NASDAQ:GMAB	Genmab AS
2024/06/03	06:30	Business Wire	Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma	NASDAQ:GMAB	Genmab AS
2024/06/01	23:00	Business Wire	Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)	NASDAQ:GMAB	Genmab AS
2024/05/29	00:29	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/05/24	06:00	Business Wire	Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting	NASDAQ:GMAB	Genmab AS
2024/05/22	00:38	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/05/22	00:18	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/05/22	00:10	Business Wire	Genmab Completes Acquisition of ProfoundBio	NASDAQ:GMAB	Genmab AS
2024/05/14	23:05	Business Wire	Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress	NASDAQ:GMAB	Genmab AS
2024/05/14	00:29	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/04/30	07:40	Business Wire	TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer	NASDAQ:GMAB	Genmab AS
2024/04/30	07:40	Business Wire	FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer	NASDAQ:GMAB	Genmab AS
2024/04/03	14:35	Business Wire	Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio	NASDAQ:GMAB	Genmab AS
2024/03/12	02:43	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS